Quantamental Technologies LLC acquired a new stake in shares of Mirati Therapeutics Inc (NASDAQ:MRTX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 577 shares of the biotechnology company’s stock, valued at approximately $59,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Aperio Group LLC bought a new stake in Mirati Therapeutics in the second quarter worth about $50,000. First Mercantile Trust Co. acquired a new stake in Mirati Therapeutics during the 2nd quarter worth about $89,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Mirati Therapeutics by 19.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,422 shares of the biotechnology company’s stock worth $146,000 after buying an additional 235 shares during the period. Strs Ohio acquired a new stake in Mirati Therapeutics during the 2nd quarter worth about $154,000. Finally, Sigma Planning Corp acquired a new stake in Mirati Therapeutics during the 2nd quarter worth about $201,000.

In related news, CEO Charles M. Baum sold 51,810 shares of Mirati Therapeutics stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $86.22, for a total value of $4,467,058.20. Following the sale, the chief executive officer now owns 117,851 shares of the company’s stock, valued at approximately $10,161,113.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Boxer Capital, Llc sold 725,008 shares of Mirati Therapeutics stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $98.30, for a total value of $71,268,286.40. The disclosure for this sale can be found here. In the last three months, insiders sold 845,360 shares of company stock worth $82,651,250. 4.86% of the stock is owned by insiders.

Several equities research analysts recently commented on the company. Leerink Swann set a $118.00 price target on Mirati Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 31st. B. Riley decreased their target price on Mirati Therapeutics from $92.00 to $83.00 and set a “neutral” rating on the stock in a report on Wednesday. JPMorgan Chase & Co. cut Mirati Therapeutics from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $101.00 to $85.00 in a report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $117.00 target price on shares of Mirati Therapeutics in a report on Tuesday, August 6th. Finally, Barclays raised their price target on Mirati Therapeutics from $85.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $98.60.

Mirati Therapeutics stock traded up $0.92 during midday trading on Friday, reaching $85.63. The stock had a trading volume of 9,497 shares, compared to its average volume of 468,951. The firm’s fifty day simple moving average is $90.90 and its 200-day simple moving average is $83.56. Mirati Therapeutics Inc has a 1-year low of $28.50 and a 1-year high of $111.99. The stock has a market capitalization of $3.13 billion, a P/E ratio of -26.90 and a beta of 2.07.

Mirati Therapeutics (NASDAQ:MRTX) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.08). The company had revenue of $0.58 million during the quarter. As a group, equities analysts anticipate that Mirati Therapeutics Inc will post -5.09 EPS for the current year.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Read More: Beige Book

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.